KLRD1 and neoplasm: However, it is important to recognize several obstacles to overcome when moving from preclinical research to clinical applications, such as tumor heterogeneity and safety issues like neurological toxicity, immunosuppression, and off-target effects which can damage healthy tissues due to cross-reactivity between the CAR-NK cell receptor and antigens present on normal cells.